Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics, Inc. stock has experienced several significant events and price movements. In April 2024, ARCA biopharma and Oruka Therapeutics combined their businesses in an all-stock transaction, with a 1-for-12 reverse stock split. In September 2025, Oruka Therapeutics announced a $180 million private placement and raised over $475 million during its go-public transaction in 2024. Positive interim data from the Phase 1 study of ORKA-001 was announced in September 2025, and the FDA cleared the Phase 2a EVERLAST-A trial of ORKA-001 in moderate-to-severe psoriasis. First-in-human dosing for ORKA-001 began in the first quarter of 2025, and the company plans to start first-in-human dosing of ORKA-002 in the third quarter of 2025. Barclays initiated coverage with an "Overweight" recommendation in October 2025. BTIG Research reiterated a "Buy" recommendation in September 2025. Guggenheim initiated coverage with a "Buy" rating and a $60.00 price target in October 2025. Wedbush reiterated an "Outperform" rating and a $40.00 price objective in August 2025. Wall Street Zen downgraded Oruka Therapeutics from a "Hold" to a "Sell" rating in October 2025. The stock has received a consensus rating of "Moderate Buy" from analysts, with an average target price of $41.80 to $44.00. The stock price has shown significant volatility, with an 82.13% rise in the last month and a 94.5% return over the past 90 days, but the one-year total shareholder return was slightly negative at -2.6%.

Direct demand seasonality is not explicitly stated as a significant factor for Oruka Therapeutics, Inc.'s products and services. Demand for its products is likely driven by disease prevalence and treatment efficacy rather than seasonal fluctuations. There is an indication of seasonality in the company's stock performance, with historical bias leaning short in October and a statistically strong window culminating around November 13, 2025.

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for chronic skin diseases, particularly psoriasis, and other inflammatory and immunology indications. The company is dedicated to developing innovative therapies to provide patients with chronic skin diseases the greatest possible freedom from their condition through high rates of complete disease clearance and infrequent dosing. The company's pipeline includes ORKA-001, a novel IL-23p19 monoclonal antibody in Phase 1 trials; ORKA-002, an IL-17A and IL-17F inhibitor; ORKA-003, a product targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. The company's strategy involves developing potentially best-in-class, long-acting antibodies against validated targets and is headquartered in Menlo Park, California.

Oruka Therapeutics, Inc. is headquartered in Menlo Park, California, United States. Specific operational locations beyond its headquarters are not extensively detailed in the provided information.

No specific events negatively impacting Oruka Therapeutics, Inc.'s brand reputation have been identified in the provided information. The company's public image is built around its mission to develop novel biologics that aim to set a new standard for the treatment of chronic skin diseases, particularly psoriasis, by offering high rates of complete disease clearance with infrequent dosing.

Oruka Therapeutics, Inc. has a significant portion of its stock owned by institutional shareholders. Major institutional owners include Fmr Llc, VR Adviser, LLC, Fairmount Funds Management LLC, BlackRock, Inc., Rtw Investments, Lp, Deep Track Capital, LP, Vanguard Group Inc, Braidwell Lp, Commodore Capital Lp, Jefferies Financial Group Inc., Cannon Global Investment Management LLC, Candriam S.C.A., AlphaQuest LLC, Affinity Asset Advisors LLC, and Venrock Healthcare Capital Partners III, L.P. Key individual and insider shareholders include Scott D. Sandell, Ravi Viswanathan, Forest Baskett, and Anthony A. Florence Jr.